Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.45 |
| ▸ | UGCG | Q16739 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434659 | 1.00 | ROCK2 (0.45) | ROCK2ROCK1UGCGSLC6A2OPRK1 | |
| SCHEMBL10083739 | 0.91 | ROCK2 (0.37) | ROCK2ROCK1UGCGOPRK1ALPL | |
| SCHEMBL15385533 | 0.91 | ROCK2 (0.37) | ROCK2ROCK1UGCGOPRK1ALPL | |
| SCHEMBL460483 | 0.89 | CDC7 (0.39) | ROCK2ROCK1OPRK1 | |
| SCHEMBL460484 | 0.89 | CDC7 (0.39) | ROCK2ROCK1OPRK1 | |
| SCHEMBL433021 | 0.89 | TRPV1 (0.37) | ROCK2ROCK1OPRK1 | |
| SCHEMBL433022 | 0.89 | TRPV1 (0.37) | ROCK2ROCK1OPRK1 | |
| SCHEMBL434875 | 0.89 | TRPV1 (0.42) | ROCK2ROCK1 | |
| SCHEMBL15385515 | 0.89 | TRPV1 (0.42) | ROCK2ROCK1 | |
| SCHEMBL435712 | 0.88 | TRPV1 (0.36) | ROCK2ROCK1SLC6A2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | claimed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | claimed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | claimed |
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | ROCK2 1728/4885ROCK1 1088/4885UGCG 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.